Glivec in Ph Positive Lymphoblastic Leukemia
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00388895|
Recruitment Status : Completed
First Posted : October 17, 2006
Last Update Posted : November 19, 2008
|Condition or disease||Intervention/treatment||Phase|
|Acute Lymphoblastic Leukemia Cromosome Philadelphia Positive||Drug: chemotherapy Drug: Glivec||Phase 2|
|Study Type :||Interventional (Clinical Trial)|
|Enrollment :||35 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||Positive Ph Acute Lymphoblastic Leucemia With Intensive Induction Chemotherapy and Glivec, Before and After the Hematopoetic Progenitor Transplant|
|Study Start Date :||June 2002|
|Actual Primary Completion Date :||October 2006|
|Actual Study Completion Date :||October 2007|
- % positive Ph LLA with RC alter the Glivec and induction chemotherapy treatment.
- Discover if is possible to treat patients with Glivec plus Standard consolidation treatment.
- Discover the Glivec effect over ERM during consolidation treatment and alter transplant
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00388895
|Study Chair:||Ribera Josep Mª, Dr||Germans Trias i Pujol Hospital|